A Safety, Efficacy and Pharmacokinetic Study of BTCT4465A (Mosunetuzumab) as a Single Agent and Combined With Atezolizumab in Non-Hodgkin's Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)
PHASE1
This is a Phase 1/2 dose-escalation study of BTCT4465A (Mosunetuzumab) admi...
Status
Completed
Location
University of California San Diego Moores Cancer Center
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma
PHASE1
This study will evaluate the safety, efficacy, and pharmacokinetics of mosu...
Status
Active Not Recruiting
Location
UCSF/Hematology, Blood & Marrow Transplant, And Cellular Therapy (HBC) Program
Comparing the Effectiveness of the Immunotherapy Agents Rituximab or Mosunetuzumab in Patients With Nodular Lymphocyte-Predominant Hodgkin Lymphoma, NORM Trial
PHASE2
This phase II trial compares mosunetuzumab to the usual treatment (rituxima...
A Study Evaluating Efficacy and Safety of Mosunetuzumab in Combination With Polatuzumab Vedotin Compared to Rituximab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
PHASE3
This study will assess the efficacy and safety of mosunetuzumab in combinat...
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab + Lenalidomide (+Len), and the Safety, Tolerability, and Pharmacokinetics of SC Versus IV Mosunetuzumab + Len in Participants With Follicular Lymphoma
PHASE1
This study will evaluate the safety, efficacy, pharmacokinetics, and immuno...